Published

Behavioral effects of psychedelic and non-psychedelic serotonin 2A receptor agonist drugs in pigs

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2026-01-01
Source: OpenAlex
DOI: 10.1016/j.nsa.2025.106824
PubMed: Unavailable

Authors

CA Madsen M. Navarro E. Kolesnik D. Kazani V. Shalgunov M. Zabrocki A. Nasser D. Luethi F. Holze M.E. Liechti S.S. Johansen M.K.K. Nielsen H.D. Hansen G.M. Knudsen

Watch author

Derived topics and classifications

psilocybin psilocin Pharmacology Mechanism of Action Receptor Pharmacology Toxicity Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Behavioral effects of psychedelic and non-psychedelic serotonin 2A receptor agonist drugs in pigs2026-01-01

Related papers

‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injuryInternal Medicine Journal · 2026-01-01 Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto RatsPsychedelic Medicine · 2025-12-16 Precision Functional Brain Mapping to Understand the Mechanisms of PsilocybinClinicalTrials.gov · 2025-10-31 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01 Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2025-05-14 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29 Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.Annals of medicine and surgery (2012) · 2026-01-01 Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signalingInternational Immunopharmacology · 2025-06-01